Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Protocols in Critically Ill Patients in Alzahra Hospital, Isfahan, Iran
Background: During the COVID-19 pandemic, different drug protocols were used to treat and manage patients. Considering the diversity in these protocols and the high costs associated with the disease, we aimed to evaluate the costs and effects of the most common therapeutic protocols among criticall...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Research Center for Rational Use of Drugs (RCRUD)
2024-12-01
|
| Series: | Journal of Pharmaceutical Care |
| Subjects: | |
| Online Access: | https://jpc.tums.ac.ir/index.php/jpc/article/view/765 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841558608896065536 |
|---|---|
| author | Majid Davari Sarah Mousavi Mohammad Reza Maracy Elahe Khorasani Masih Zamani Mohammadreza Amirsadri |
| author_facet | Majid Davari Sarah Mousavi Mohammad Reza Maracy Elahe Khorasani Masih Zamani Mohammadreza Amirsadri |
| author_sort | Majid Davari |
| collection | DOAJ |
| description |
Background: During the COVID-19 pandemic, different drug protocols were used to treat and manage patients. Considering the diversity in these protocols and the high costs associated with the disease, we aimed to evaluate the costs and effects of the most common therapeutic protocols among critically ill COVID-19 patients.
Methods: In this retrospective cross-sectional study, a total of 235 critically ill COVID-19 patients were randomly selected from those hospitalized in the Intensive Care Units of Alzahra Hospital, Isfahan, Iran, between July and December 2020. The study assessed demographic data, outcomes (mortality rate), severity of the disease (SOFA score), and average direct costs of each therapeutic regimen. Statistical analysis included Cox-Regression analysis and Kaplan-Meier survival curve.
Results: We identified 21 therapeutic protocols based on prescribed medications, with six protocols being the most commonly used. The protocol containing dexamethasone + methylprednisolone showed the highest survival probability (0.79) with a median length of hospital stay of 17 days. Cost evaluation revealed that the dexamethasone protocol had the lowest average cost per patient, while the dexamethasone + methylprednisolone + remdesivir protocol had the highest. Hoteling costs accounted for 45% of the total costs, followed by medication costs (25%).
Conclusion: The dexamethasone + methylprednisolone therapeutic regimen demonstrated the highest effectiveness in terms of survival probability and was also associated with the lowest average cost per patient.
|
| format | Article |
| id | doaj-art-ffb8d870b4b2473cb86a892e334064dd |
| institution | Kabale University |
| issn | 2322-4630 2322-4509 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Research Center for Rational Use of Drugs (RCRUD) |
| record_format | Article |
| series | Journal of Pharmaceutical Care |
| spelling | doaj-art-ffb8d870b4b2473cb86a892e334064dd2025-01-06T08:43:48ZengResearch Center for Rational Use of Drugs (RCRUD)Journal of Pharmaceutical Care2322-46302322-45092024-12-0112410.18502/jpc.v12i4.17453Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Protocols in Critically Ill Patients in Alzahra Hospital, Isfahan, IranMajid Davari0Sarah Mousavi1Mohammad Reza Maracy2Elahe Khorasani3Masih Zamani4Mohammadreza Amirsadri5Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Pharmaceutical Management & Economics Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical SciencesDepartment of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, IranDepartment of Epidemiology and Biostatistics, School of Health, Isfahan University of Medical Sciences, Isfahan, IranCentre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, Montreal, QC, Canada.Department of Pharmacoeconomics and Pharmaceutical Administration, School of Pharmacy, Pharmaceutical Management & Economics Research Center, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences1Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran. 2 Isfahan Pharmaceutical Sciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Background: During the COVID-19 pandemic, different drug protocols were used to treat and manage patients. Considering the diversity in these protocols and the high costs associated with the disease, we aimed to evaluate the costs and effects of the most common therapeutic protocols among critically ill COVID-19 patients. Methods: In this retrospective cross-sectional study, a total of 235 critically ill COVID-19 patients were randomly selected from those hospitalized in the Intensive Care Units of Alzahra Hospital, Isfahan, Iran, between July and December 2020. The study assessed demographic data, outcomes (mortality rate), severity of the disease (SOFA score), and average direct costs of each therapeutic regimen. Statistical analysis included Cox-Regression analysis and Kaplan-Meier survival curve. Results: We identified 21 therapeutic protocols based on prescribed medications, with six protocols being the most commonly used. The protocol containing dexamethasone + methylprednisolone showed the highest survival probability (0.79) with a median length of hospital stay of 17 days. Cost evaluation revealed that the dexamethasone protocol had the lowest average cost per patient, while the dexamethasone + methylprednisolone + remdesivir protocol had the highest. Hoteling costs accounted for 45% of the total costs, followed by medication costs (25%). Conclusion: The dexamethasone + methylprednisolone therapeutic regimen demonstrated the highest effectiveness in terms of survival probability and was also associated with the lowest average cost per patient. https://jpc.tums.ac.ir/index.php/jpc/article/view/765Covid-19Cost EvaluationIntensive Care UnitTherapeutic Regimen |
| spellingShingle | Majid Davari Sarah Mousavi Mohammad Reza Maracy Elahe Khorasani Masih Zamani Mohammadreza Amirsadri Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Protocols in Critically Ill Patients in Alzahra Hospital, Isfahan, Iran Journal of Pharmaceutical Care Covid-19 Cost Evaluation Intensive Care Unit Therapeutic Regimen |
| title | Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Protocols in Critically Ill Patients in Alzahra Hospital, Isfahan, Iran |
| title_full | Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Protocols in Critically Ill Patients in Alzahra Hospital, Isfahan, Iran |
| title_fullStr | Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Protocols in Critically Ill Patients in Alzahra Hospital, Isfahan, Iran |
| title_full_unstemmed | Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Protocols in Critically Ill Patients in Alzahra Hospital, Isfahan, Iran |
| title_short | Evaluation of the Costs and Outcomes of COVID-19 Therapeutic Protocols in Critically Ill Patients in Alzahra Hospital, Isfahan, Iran |
| title_sort | evaluation of the costs and outcomes of covid 19 therapeutic protocols in critically ill patients in alzahra hospital isfahan iran |
| topic | Covid-19 Cost Evaluation Intensive Care Unit Therapeutic Regimen |
| url | https://jpc.tums.ac.ir/index.php/jpc/article/view/765 |
| work_keys_str_mv | AT majiddavari evaluationofthecostsandoutcomesofcovid19therapeuticprotocolsincriticallyillpatientsinalzahrahospitalisfahaniran AT sarahmousavi evaluationofthecostsandoutcomesofcovid19therapeuticprotocolsincriticallyillpatientsinalzahrahospitalisfahaniran AT mohammadrezamaracy evaluationofthecostsandoutcomesofcovid19therapeuticprotocolsincriticallyillpatientsinalzahrahospitalisfahaniran AT elahekhorasani evaluationofthecostsandoutcomesofcovid19therapeuticprotocolsincriticallyillpatientsinalzahrahospitalisfahaniran AT masihzamani evaluationofthecostsandoutcomesofcovid19therapeuticprotocolsincriticallyillpatientsinalzahrahospitalisfahaniran AT mohammadrezaamirsadri evaluationofthecostsandoutcomesofcovid19therapeuticprotocolsincriticallyillpatientsinalzahrahospitalisfahaniran |